Ian Harrison, PhD, University College London, London, UK, shares an overview of imaging strategies that enable quantification of glymphatic function in disease models. Impairment of the glymphatic system has been seen in neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), and there is therefore a great interest in understanding its role in toxic protein accumulation and its potential as a therapeutic target. One method of visualizing glymphatic flow in animal models is by use of contrast agents, such as gadolinium-DTPA enhanced magnetic resonance imaging. Another common technique is ex vivo fluorescence microscopy of brain slices. This interview took place at The BNA 2023 International Festival of Neuroscience in Brighton, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.